Diabetic Retinopathy News and Research

RSS
In the initial stages, people with diabetic retinopathy may not notice their vision changing. Diabetics sometimes experience rapid changes in blood sugar that can temporarily cause blurry vision even when retinopathy is not present. If a person notices a few specks or spots floating in his visual field, this may mean he has developed proliferative diabetic retinopathy, the growth of abnormal new blood vessels on the retina and optic nerve. High blood sugar levels have been linked in studies to retinal blood vessel abnormalities. Blurred vision may occur when the macula--the small area at the center of the retina--swells as it fills with fluid that has leaked from retinal blood vessels. Because damage to the eye often develops slowly, early detection of diabetes and control of blood sugar through diet and medications can make a crucial difference in saving vision.

Effective diabetic retinopathy treatments include laser photocoagulation for early to moderate stages and a microsurgery called vitrectomy for repair of eyes with extensive damage. Injectable and oral medications that act on abnormal blood vessels to control diabetic retinopathy before vision loss occurs are now in development. Early detection would be key to the effectiveness of these treatments, also.
Patients with diabetes, depression more likely to develop serious eye disease

Patients with diabetes, depression more likely to develop serious eye disease

Early detection critical in preventing vision loss among Baby Boomers

Early detection critical in preventing vision loss among Baby Boomers

New convenient device can track degenerative eye disease

New convenient device can track degenerative eye disease

Novel drug delivery device can treat diabetes-related retinal damage

Novel drug delivery device can treat diabetes-related retinal damage

Positive results from RISE and RIDE Phase III trials of Genentech's Lucentis for diabetic macular edema

Positive results from RISE and RIDE Phase III trials of Genentech's Lucentis for diabetic macular edema

InNexus files patent protection for new Age-related Macular Degeneration therapeutic

InNexus files patent protection for new Age-related Macular Degeneration therapeutic

Wills Eye Institute and Thomas Jefferson University create new vision research center

Wills Eye Institute and Thomas Jefferson University create new vision research center

pSivida resubmits ILUVIEN NDA to FDA for diabetic macular edema treatment

pSivida resubmits ILUVIEN NDA to FDA for diabetic macular edema treatment

Promedior's PRM-151 clinical data in idiopathic pulmonary fibrosis to be presented at ATS 2011

Promedior's PRM-151 clinical data in idiopathic pulmonary fibrosis to be presented at ATS 2011

Study demonstrates value of MicroPulse technology for diabetic macular edema treatment

Study demonstrates value of MicroPulse technology for diabetic macular edema treatment

pSivida presents data of ILUVIEN Phase 3 trial in Diabetic Macular Edema at ARVO 2011

pSivida presents data of ILUVIEN Phase 3 trial in Diabetic Macular Edema at ARVO 2011

Promedior to present PRM-151 study data in age-related macular degeneration at ARVO meeting

Promedior to present PRM-151 study data in age-related macular degeneration at ARVO meeting

Study uses simulation model to assess cost-effective eye screenings for Americans with diabetes

Study uses simulation model to assess cost-effective eye screenings for Americans with diabetes

Bayer, Regeneron initiate two VEGF Trap-Eye Phase 3 trials in Diabetic Macular Edema

Bayer, Regeneron initiate two VEGF Trap-Eye Phase 3 trials in Diabetic Macular Edema

A2AAR-selective agonists may prevent permanent vision damage from traumatic optic nerve injury

A2AAR-selective agonists may prevent permanent vision damage from traumatic optic nerve injury

Genentech's Lucentis Phase III trials in DME meets primary endpoints

Genentech's Lucentis Phase III trials in DME meets primary endpoints

NIH: Diabetic retinopathy leads to vision loss in working-age Americans

NIH: Diabetic retinopathy leads to vision loss in working-age Americans

Genentech announces positive outcomes from Lucentis Phase III trial against DME

Genentech announces positive outcomes from Lucentis Phase III trial against DME

Regeneron submits VEGF Trap-Eye BLA to FDA for treatment of wet AMD

Regeneron submits VEGF Trap-Eye BLA to FDA for treatment of wet AMD

Statin drug may help prevent blindness in diabetics

Statin drug may help prevent blindness in diabetics

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.